What is HC Wainwright’s Forecast for Alumis FY2027 Earnings?

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Alumis in a report released on Monday, March 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($3.37) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. The business had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million.

A number of other equities analysts have also recently issued reports on ALMS. Guggenheim increased their target price on Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company boosted their price target on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. Raymond James Financial began coverage on Alumis in a research report on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $38.00 price objective on shares of Alumis in a research note on Monday. Finally, Stifel Nicolaus assumed coverage on Alumis in a report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Alumis currently has an average rating of “Moderate Buy” and an average target price of $38.60.

Alumis Stock Up 9.0%

Shares of ALMS opened at $22.03 on Tuesday. The company has a 50-day moving average price of $26.42 and a two-hundred day moving average price of $14.79. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of -7.20 and a beta of -2.15. Alumis has a 12 month low of $2.76 and a 12 month high of $30.60.

Hedge Funds Weigh In On Alumis

A number of institutional investors and hedge funds have recently bought and sold shares of ALMS. MPM Bioimpact LLC bought a new position in shares of Alumis in the fourth quarter valued at about $23,443,000. Orbimed Advisors LLC acquired a new position in Alumis during the 2nd quarter worth about $5,779,000. Velan Capital Investment Management LP bought a new stake in Alumis during the 2nd quarter worth about $4,863,000. Woodline Partners LP grew its holdings in Alumis by 809.7% during the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after acquiring an additional 1,558,660 shares during the last quarter. Finally, Samsara Biocapital LLC increased its position in Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after acquiring an additional 1,534,872 shares in the last quarter.

Insider Activity

In other Alumis news, Director James B. Tananbaum purchased 411,764 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the acquisition, the director directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This trade represents a 7.78% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Srinivas Akkaraju purchased 588,235 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were acquired at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director directly owned 1,853,488 shares in the company, valued at approximately $31,509,296. This represents a 46.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 1,823,527 shares of company stock worth $30,999,959. 40.70% of the stock is currently owned by insiders.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target sharply to $55 and kept an “outperform” rating, signaling substantial upside vs. the current share level and supporting buying interest. Article Title
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating with a $38 price target, reiterating institutional conviction and adding support for bullish flows. Article Title
• Positive Sentiment: Morgan Stanley (via a TipRanks summary) maintained a Buy rating and $38 target, citing strong Phase‑3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a clinical/data catalyst that underpins upside expectations. Article Title
• Neutral Sentiment: HC Wainwright issued FY2027 EPS estimates of ($3.37) and kept a “Buy” rating with a $25 target — the EPS forecast is materially less negative than the consensus (-$8.51), which could be read as relatively constructive, but the figure is still negative and reflects ongoing cash burn/near‑term losses.
• Negative Sentiment: HC Wainwright cut its prior price target from $40 to $25 while retaining a buy rating, a mixed signal that reduces some upside expectations and may have pressured shorter‑term sentiment. Article Title
• Negative Sentiment: On 3/30 ALMS fell roughly 11% amid profit‑taking after a ~239% yearly gain; technical selling and traders locking gains were cited as drivers of the pullback. That short‑term volatility can amplify moves when headlines on ratings/targets hit the tape. Why Is Alumis Stock Falling Monday?

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.